Literature DB >> 15479390

Functional recovery after bleeding episodes in haemophilia.

P De Kleijn1, M Gilbert, G Roosendaal, P M Poonnose, P M Narayan, N Tahir.   

Abstract

Haemophilia is characterized by intra-articular and intramuscular bleeding episodes. Although much work has been carried out into post-bleeding mechanisms in both synovial joints and muscles, the picture is not yet clear. A firm post-bleeding rehabilitation protocol is of utmost importance for people with haemophilia. The use of the International Classification of Functioning Disability and Health reveals that information worldwide is on body level, whereas the goals of patients with haemophilia implicitly aim at optimal functional recovery. This interferes much more with activities and participation in society. The Functional Independence Score for Haemophilia and the Post-bleeding Protocol Based on Functional Milestones are examples of post-bleeding approaches that deal more with function. Two cases will emphasize the value of this approach.

Entities:  

Mesh:

Year:  2004        PMID: 15479390     DOI: 10.1111/j.1365-2516.2004.00977.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

1.  The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia.

Authors:  M W Skinner; C Chai-Adisaksopha; R Curtis; N Frick; M Nichol; D Noone; B O'Mahony; D Page; J S Stonebraker; A Iorio
Journal:  Pilot Feasibility Stud       Date:  2018-02-27

2.  Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.

Authors:  Karin P M van Galen; Piet de Kleijn; Wouter Foppen; Jeroen Eikenboom; Karina Meijer; Roger E G Schutgens; Kathelijn Fischer; Marjon H Cnossen; Joke de Meris; Karin Fijnvandraat; Johanna G van der Bom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Eveline P Mauser-Bunschoten
Journal:  Haematologica       Date:  2017-06-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.